Merck & Company Inc (MRK)vsNurix Therapeutics Inc (NRIX)
MRK
Merck & Company Inc
$146.35
+3.85%
HEALTHCARE · Cap: $360.08B
NRIX
Nurix Therapeutics Inc
$27.26
+2.10%
HEALTHCARE · Cap: $2.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 9384% more annual revenue ($66.57B vs $701.94M). NRIX leads profitability with a 42.0% profit margin vs 4.8%. NRIX trades at a lower P/E of 10.1x. NRIX earns a higher WallStSmart Score of 65/100 (C+).
MRK
Hold36
out of 100
Grade: F
NRIX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Intrinsic value data unavailable for NRIX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 83.1%
Revenue surging 8426.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
ROE of -61.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : NRIX
The strongest argument for NRIX centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 42.0% and operating margin at 83.1%. Revenue growth of 8426.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : NRIX
The primary concerns for NRIX are EPS Growth, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while NRIX is a growth play — different risk/reward profiles.
NRIX carries more volatility with a beta of 1.82 — expect wider price swings.
NRIX is growing revenue faster at 8426.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
NRIX scores higher overall (65/100 vs 36/100), backed by strong 42.0% margins and 8426.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Nurix Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?